Home / 2011 (page 7)

Yearly Archives: 2011

Editor’s Note: AGEs, Errors and Teenagers

Over the past three issues we have focused on advanced glycation end-products (AGEs) — how they are formed, what they can do, and why these compounds are detrimental to our patients’ health. This week in our Homerun Slides, we are bringing you information on ways to reduce the effects of …

Read More »

Letter from the Editor: New GLP-1 Article

We have been sharing a lot of information about native GLP-1 and GLP-1 analogs, and how these compounds work to control glucose levels in our patients. Lately there has been a lot of press concerning the possible cardiovascular benefits of using these analogs in our patients. We’ve been able to …

Read More »

GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects, Part 1

Image1

Melanie Sulistio, MD, Curtis Carothers, MD, Mandeep Mange, BS, Mike Lujan, BS, Rene Ofiveros, MD, and Robert Chilton, DO Cardiovascular disease is a leading cause of death in the United States and across the world, and better therapies are constantly being sought to improve patient outcomes. Recent studies have brought …

Read More »